PipelineRSSMay 5
European regulators back new DMD gene therapy with key status
European regulators have approved a special status for SGT-003, a new gene therapy treatment for Duchenne muscular dystrophy (DMD), a serious muscle disease that affects boys. This approval, called orphan drug designation, means the treatment is recognized as addressing a rare disease with few other options. The therapy is designed to help preserve muscle strength in boys with DMD.
WHY IT MATTERSSGT-003 now has regulatory backing in both the U.S. and Europe, which accelerates its development pathway and may bring a new treatment option closer to boys with DMD who currently have limited gene therapy choices.